NCT05824767 - Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2023

Primary Completion Date

March 12, 2025

Study Completion Date

March 12, 2025

Conditions

Septic ShockVasodilatory Shock

Interventions

DRUG

Angiotensin II

Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring peptide hormone of the same name which is a component of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II (Giapreza) was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.

Trial Locations (1)

87106

University of New Mexico Health Sciences Center, Albuquerque